Skip to content
Biodatica
Start free

Evopoint Biosciences Inc.

Jinan, Shandong

OncologyADCPhase II
Sign in to watch

What changed

Phase II trial registered: XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.

Feb 2025Trial registeredFeb 7, 2025Source filing (opens the source filing in a new tab)

Momentum

35no change

Momentum 35 out of 100, unchanged since the last recompute.

Little recent filing activity, or the events on file have decayed.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    Jul 27, 2023

    Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic, Biliary Tract Cancer, Gastric Carcinoma, Gastroesophageal Junction Adenocarcinoma · RECRUITING · sponsor: Evopoint Biosciences Inc. · XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.

    ClinicalTrials.gov · NCT06792435 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources